Please login to the form below

Not currently logged in
Email:
Password:

Almac appoints Charlie Morris as VP new products and services in clinical technologies division

Joins from Princeton Financial Systems

Charlie Morris, AlmacCharlie Morris (pictured) has joined the Almac Group's clinical technologies division as VP of new products and services.

According to the company, which provides services to the pharma industry, he will oversee the development of its IXRS technology to manage patients, supplies, and clinical trial data.

Morris joins Almac from Princeton Financial Systems where he served as chief technology officer for more than ten years.

Prior to this, he served as director of applications development at Telescan, building and implementing teleradiology systems. He began his career in military contracts where he developed flight simulation, anti-submarine warfare, and naval intelligence systems.

Jim Murphy, president of Almac's clinical technologies unit, said: “Given [Morris'] breadth of system development leadership experience, we are highly confident in his ability to align the new products and services department to support accelerated innovation of Almac's technology.

“We welcome Charlie to Almac and know he will have a profound impact on the expansion of our technology offerings and client relationships.”

18th December 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics